Apricus Biosciences, Inc.
) recently announced that its erectile dysfunction (ED) drug,
Vitaros, has been approved under the European Decentralized
Apricus, along with its commercialization partners, Sandoz,
) and Bracco, will now look to obtain national phase approvals to
make Vitaros available in all territories across Europe.
Results from a phase III study evaluating the safety and
efficacy of Vitaros and its long-term use in men who did not
respond to phosphodiesterase type 5 (PDE-5) inhibitors like
Viagra (n=325) showed that multiple doses of Vitaros (200 mcg and
300 mcg) improved erections in patients.
Apricus' marketing approval application for Vitaros designated
Netherlands as the Reference Member State (RMS) on behalf of nine
other European Concerned Member States (France, Germany, Italy,
UK, Ireland, Spain, Sweden, Belgium and Luxembourg) who
participated in the procedure.
Although Apricus believes that Vitaros has the potential to
capture a good share of the PDE-5 inhibitor market (worth
approximately $1 billion) once launched, we note that the market
currently has big companies like
Eli Lilly and Company
The company also mentioned that it will continue to seek
additional partnership agreements for Vitaros in the rest of the
European and global markets.
Apricus was recently engaged in a $17.1 million financing. It
also divested multiple non-core assets and has also streamlined
its global operations. This should allow the company to focus on
its lead assets for male and female sexual health, namely,
Vitaros and Femprox.
Apricus presently carries a Zacks Rank #4 (Sell). Currently,
) look more attractive with a Zacks Rank #1 (Strong Buy).
APPRICUS BIOSCI (APRI): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
TAKEDA PHARMACT (TKPYY): Get Free Report
To read this article on Zacks.com click here.